Changing concepts of hormone receptor-positive advanced breast cancer therapy

Clinical Breast Cancer

Volumn 13, Issue 3, 2013, Pages 159-166

  Chlebowski, Rowan T ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Advanced breast cancer; Endocrine therapy; Everolimus

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG FATALITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; LOADING DRUG DOSE; MOUTH ULCER; MULTICENTER STUDY (TOPIC); NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS;

EID: 84876698884     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.11.002     Document Type: Note

References (49)

1. C. Bernard-Marty, F. Cardoso, M.J. Piccart Facts and controversies in systemic treatment of metastatic breast cancer Oncologist 9 2004 617 632
2. R.W. Carlson, D.C. Allred, B.O. Anderson Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw 10 2012 821 829
3. M.E. Hammond, D.F. Hayes, M. Dowsett American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer Arch Pathol Lab Med 134 2010 907 922
4. D.C. Allred Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer Mod Pathol 23 suppl 2 2010 S52 S59
5. Early Breast Cancer Trialist Group (EBCTCG) C. Davies, J. Godwin, R. Gray et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
6. J.M. Bartlett, C.L. Brookes, T. Robson Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol 29 2011 1531 1538
7. T. Iwamoto, D. Booser, V. Valero Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry J Clin Oncol 30 2012 729 734
8. A. Franco, N. Col, R.T. Chlebowski Discordance in estrogen (ER) and progestin (PR) status between primary and metastatic breast cancer: a meta-analysis Proc Am Soc Clin Oncol 23 2004 5391
9. E. Amir, W.S. Ooi, C. Simmons Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies Clin Oncol (R Coll Radiol) 20 2008 763 768
10. C. Simmons, N. Miller, W. Geddie Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 2009 1499-054
11. L.S. Lindström, E. Karlsson, U.M. Wilking Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 2012 2601 2608
12. C.K. Osborne, R. Schiff Mechanisms of endocrine resistance in breast cancer Annu Rev Med 62 2011 233 247
13. B. Kaufman, J.R. Mackey, M.R. Clemens Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 2009 5529 5537
14. S. Johnston, J. Pippen, X. Pivot Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 2009 5538 5546
15. C. Barrios, J.F. Forbes, W. Jonat The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 23 2012 1378 1386
16. N. Wilcken, J. Hornbuckle, D. Ghersi Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Sys Rev 2 2003 CD002747
17. S. Howell, A. Howell Treatment of metastatic breast cancer: endocrine therapy J.R. Harris, Diseases of the Breast 4th ed. 2010 Lippincott Williams & Wilkins Philadelphia, PA 856 876
18. J.G. Klijn, R.W. Blamey, F. Boccardo Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J Clin Oncol 19 2001 343 353
19. K.L. Cheung, A. Agrawal, E. Folkerd Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women Eur J Cancer 46 2010 2936 2942
20. R. Bartsch, Z. Bago-Horvath, A. Berghoff Ovarian function suppression and fulvestrant as endocrine therapy in postmenopausal women with metastatic breast cancer Eur J Cancer 48 2012 1932 1938
21. US Food and Drug Administration drugs@fda http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm Accessed: November 23, 2012
22. L. Estévez, I. Alvarez, I. Tusquets Finding the right dose of fulvestrant in breast cancer Cancer Treat Rev 39 2013 136 141
23. A. Di Leo, G. Jerusalem, L. Petruzelka Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 2010 4594 4600
24. F. Cardoso, J. Bischoff, E. Brain A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women Cancer Treat Rev 2012 [Epub ahead of print]
25. A. Howell, J.F. Robertson, J. Quaresma Albano Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
26. J.M. Nabholtz, J. Bonneterre, A. Buzdar Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results Eur J Cancer 39 2003 1684 1689
27. H. Mouridsen, M. Gershanovich, Y. Sun Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101 2109
28. R.J. Paridaens, L.Y. Dirix, L.V. Beex Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 26 2008 4883 4890
29. J. Bonneterre, A. Buzdar, J.M. Nabholtz Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247 2258
30. A. Howell, J.F. Robertson, P. Abram Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 2004 1605 1613
31. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer: SWOG S0226. N Engl J Med 1012; 367:435-44.
32. J. Bergh, P.E. Jönsson, E.K. Lidbrink FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer J Clin Oncol 30 2012 1919 1925
33. J.F. Robertson, A. Llombart-Cussac, J. Rolski Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study J Clin Oncol 27 2009 4530 4535
34. J.F.R. Robertson, J.P.O. Lindemann, A. Llombart-Cussac Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study Breast Cancer Res Treat 136 2012 503 511
35. A.U. Buzdar, W. Jonat, A. Howell Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials Arimidex Study Group Cancer 83 1998 1142 1152
36. A. Howell, J.F. Robertson, J. Quaresma Albano Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
37. C.K. Osborne, J. Pippen, S.E. Jones Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
38. S. Chia, W. Gradishar, L. Mauriac Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 2008 1664 1670
39. S. Johnston, L.S. Kilburn, P. Ellis 2LBA fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor - first results of the SoFea trial (Cruke-03-021 and Cruk-09-007) (ISRCTN44195747) Eur J Cancer 48 2012 S2
40. K.I. Pritchard, J. Rolski, Z. Papai Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) Breast Cancer Res Treat 123 2010 453 461
41. C. Villarreal-Garza, J. Cortes, F. Andre MTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions Ann Oncol 23 2012 2526 2535
42. R. O'Regan, N.N. Hawk MTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy Expert Opin Ther Targets 15 2011 859 872
43. M. Miyazawa, M. Yasuda, M. Fujita Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma Pathol Int 59 2009 19 27
44. B.K. Linderholm, H. Hellborg, U. Johansson Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer Breast Cancer Res Treat 125 2011 457 465
45. T. Bachelot, C. Bourgier, C. Cropet Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study J Clin Oncol 30 2012 2718 2724
46. J. Baselga, M. Campone, M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
47. L. Albiges, F. Chammings, B. Duclos Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma Ann Oncol 23 2012 1943 1953
48. A. Efeyan, D.M. Sabatini MTOR and cancer many loops in one pathway Curr Opin Cell Biol 22 2010 169 176
49. H.J. Burstein Novel agents and future directions for refractory breast cancer Semin Oncol 38 suppl 2 2011 S17 S24